Related Articles [Corticosteroids in the management of advanced prostate cancer]. Urologe A. 2017 Feb;56(2):217-223 Authors: Kübler H Abstract Corticosteroids have been widely used for decades in cancer therapy, predominantly due to their anti-inflammatory activity. In the treatment of metastatic castration-resistant prostate cancer (mCRPC), corticosteroids play an important role both in the management of tumor-related symptoms, especially bone metastasis-related pain, and as concomitant treatment to counteract side effects associated with approved active prostatic anticancer agents such as docetaxel, cabazitaxel, and abiraterone acetate. In association with abiraterone acetate, low-dose corticosteroids (prednisone or prednisolone) reduce the mineralocorticoid side effects of abiraterone. In addition,…
Origen: [Corticosteroids in the management of advanced prostate cancer]. – PubMed

Related Articles Borderline left ventricle: Trying to see the forest for the trees. J Thorac Cardiovasc Surg. 2017 08;154(2):570-571 Authors: Bacha E PMID: 28434618 [PubMed – indexed for MEDLINE]
Origen: Borderline left ventricle: Trying to see the forest for the trees. – PubMed

Related Articles Predictors of response to corticosteroids for dyspnea in advanced cancer patients: a preliminary multicenter prospective observational study. Support Care Cancer. 2017 Apr;25(4):1169-1181 Authors: Mori M, Shirado AN, Morita T, Okamoto K, Matsuda Y, Matsumoto Y, Yamada H, Sakurai H, Aruga E, Kaneishi K, Watanabe H, Yamaguchi T, Odagiri T, Hiramoto S, Kohara H, Matsuo N, Katayama H, Nishi T, Matsui T, Iwase S Abstract PURPOSE: Although corticosteroids can relieve dyspnea in advanced cancer patients, factors predicting the response remain unknown. We aimed to explore potential factors predicting the response to corticosteroids for dyspnea in advanced cancer patients. METHODS:…
Origen: Predictors of response to corticosteroids for dyspnea in advanced cancer patients: a preliminary multicenter prospective observational study. – PubMed

Related Articles Barriers to end-of-life discussions among hematologists: A qualitative study. Palliat Med. 2018 05;32(5):1021-1029 Authors: Prod’homme C, Jacquemin D, Touzet L, Aubry R, Daneault S, Knoops L Abstract BACKGROUND: Integrated palliative care is correlated with earlier end-of-life discussion and improved quality of life. Patients with haematological malignancies are far less likely to receive care from specialist palliative or hospice services compared to other cancers. AIM: The main goal of this study was to determine hematologists’ barriers to end-of-life discussions when potentially fatal hematological malignancies recur. DESIGN: Qualitative grounded theory study using individual interviews. SETTING/PARTICIPANTS: Hematologists ( n = 10) from four…
Origen: Barriers to end-of-life discussions among hematologists: A qualitative study. – PubMed

Related Articles The impact of community-based palliative care on acute hospital use in the last year of life is modified by time to death, age and underlying cause of death. A population-based retrospective cohort study. PLoS One. 2017;12(9):e0185275 Authors: Spilsbury K, Rosenwax L, Arendts G, Semmens JB Abstract OBJECTIVE: Community-based palliative care is known to be associated with reduced acute care health service use. Our objective was to investigate how reduced acute care hospital use in the last year of life varied temporally and by patient factors. METHODS: A retrospective cohort study of the last year of life of 12,763…
Origen: The impact of community-based palliative care on acute hospital use in the last year of life is modified by time to death, age and underlying cause of death. A population-based retrospective cohort study. – PubMed